Teva has reviewed its core therapeutic areas towards long-term commitment to develop patient-centric solutions and significantly grow its specialty medicines business. The company will invest in Central Nervous System (including multiple sclerosis, neurodegenerative diseases and pain) and Respiratory (including asthma and chronic obstructive pulmonary disease). Teva has also identified 14 pipeline projects for discontinuation or divestment, for a total amount of more than $150 million in R&D costs in 2015 and in excess of $200 million for each of 2016 and 2017.